

Koen van Besien

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6302542/publications.pdf>

Version: 2024-02-01

392
papers

15,783
citations

19657

61
h-index

22166

113
g-index

399
all docs

399
docs citations

399
times ranked

10135
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. <i>Haematologica</i> , 2022, 107, 1608-1618.	3.5	16
2	Adenovirus viremia after <i>in vivo</i> T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes. <i>Leukemia and Lymphoma</i> , 2022, 63, 435-442.	1.3	2
3	C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy. <i>Bone Marrow Transplantation</i> , 2022, 57, 1445-1447.	2.4	9
4	Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell Depleted Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 618.e1-618.e10.	1.2	10
5	Phase I study of AIC100 in relapsed and/or refractory advanced thyroid cancer and anaplastic thyroid cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6093-6093.	1.6	0
6	Cord blood maternal microchimerism following unrelated cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1090-1098.	2.4	11
7	Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1629-1638.	1.3	1
8	Colonization with Gastrointestinal Pathogens Prior to Hematopoietic Cell Transplantation and Associated Clinical Implications. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 499.e1-499.e6.	1.2	2
9	Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021, 5, 44.	5.4	20
10	High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8021-8021.	1.6	0
11	Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7533-7533.	1.6	2
12	Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2021, 73, 1257-1265.	5.8	24
13	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 993.e1-993.e8.	1.2	4
14	Maintenance therapy after allogeneic transplant for acute myeloid leukemia: great expectations. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-4.	1.3	0
15	Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults. <i>Leukemia and Lymphoma</i> , 2021, , 1-5.	1.3	3
16	Is less more? Viewpoint on empiric vancomycin therapy of fever and neutropenia after allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2021, 62, 255-256.	1.3	0
17	Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [lomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies. <i>Blood</i> . 2021. 138. 1791-1791.	1.4	6
18	Screening Chest CT Prior to Allogenic Transplantation - High Rates of Occult Abnormalities. <i>Blood</i> , 2021, 138, 1777-1777.	1.4	2

#	ARTICLE	IF	CITATIONS
19	121â€¦ICAM-1-specific affinity tuned CAR T cells expressing SSTR2 for real-time imaging. , 2021, 9, A130-A130.		0
20	Allogeneic transplant graft source â€“ conditioning â€“ GVHD prophylaxis: donâ€™t mix and match!. Leukemia and Lymphoma, 2021, , 1-3.	1.3	1
21	Reply to Caldwell et al. Clinical Infectious Diseases, 2021, , .	5.8	0
22	Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2020, 71, 1693-1700.	5.8	17
23	Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 789-797.	2.0	11
24	Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma, 2020, 61, 3024-3026.	1.3	2
25	Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. Ca-A Cancer Journal for Clinicians, 2020, 70, 349-354.	329.8	18
26	Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Advances, 2020, 4, 5146-5156.	5.2	5
27	Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected?. Leukemia and Lymphoma, 2020, 61, 2783-2784.	1.3	0
28	Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir. Transplant Infectious Disease, 2020, 22, e13336.	1.7	8
29	Cord blood transplants supported by unrelated donor CD34+ progenitor cells. Bone Marrow Transplantation, 2020, 55, 2298-2307.	2.4	3
30	Alternative Donor Transplantation for Lymphoid Malignancies: How Far We Have Come. Journal of Clinical Oncology, 2020, 38, 1501-1504.	1.6	1
31	Hematological manifestations of COVID-19. Leukemia and Lymphoma, 2020, 61, 2790-2798.	1.3	30
32	Seven Years of Haplo-Cord Transplantation: Immune Reconstitution and Outcomes Using Anti-Thymocyte Globulin. Biology of Blood and Marrow Transplantation, 2020, 26, S309.	2.0	1
33	Combining haplo-identical and cord blood stem cell grafts â€“ might the whole be greater than the sum of its parts?. Leukemia and Lymphoma, 2020, 61, 753-756.	1.3	2
34	An update on options of therapy for aggressive mantle cell lymphoma. Leukemia and Lymphoma, 2020, 61, 2036-2049.	1.3	0
35	Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Advances, 2020, 4, 560-572.	5.2	88
36	<i>KIR B</i> donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Advances, 2020, 4, 740-754.	5.2	42

#	ARTICLE	IF	CITATIONS
37	MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. <i>Clinical and Experimental Immunology</i> , 2020, 203, 96-104.	2.6	44
38	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
39	High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 30-31.	1.4	2
40	Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered. <i>Blood</i> , 2020, 136, 42-44.	1.4	3
41	Cellular Therapy for Follicular Lymphoma. , 2020, , 165-186.		0
42	Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas. <i>Blood</i> , 2020, 136, 43-44.	1.4	1
43	Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis. <i>Blood</i> , 2020, 136, 35-36.	1.4	7
44	A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas. <i>Blood</i> , 2020, 136, 7-8.	1.4	3
45	Clinical Characteristics and Risk Factors for Adverse Outcomes of Influenza Infections in Hematopoietic Stem Cell Transplant Recipients. <i>Blood</i> , 2020, 136, 22-22.	1.4	0
46	A renaissance for autologous transplantation in follicular lymphoma?. <i>Leukemia and Lymphoma</i> , 2019, 60, 3-5.	1.3	1
47	Donor graft genotypes versus leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1606-1607.	1.3	0
48	Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. <i>Scientific Reports</i> , 2019, 9, 10634.	3.3	53
49	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	3.0	24
50	The application of precision medicine in diagnosing familial Mediterranean fever. <i>Leukemia and Lymphoma</i> , 2019, 60, 2091-2093.	1.3	0
51	INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL. <i>Hematological Oncology</i> , 2019, 37, 505-507.	1.7	2
52	High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2027-2038.	2.4	20
53	Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. <i>Leukemia and Lymphoma</i> , 2019, 60, 1626-1631.	1.3	23
54	Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. <i>Experimental Hematology and Oncology</i> , 2019, 8, 1.	5.0	21

#	ARTICLE	IF	CITATIONS
55	Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. <i>Leukemia and Lymphoma</i> , 2019, 60, 1693-1696.	1.3	22
56	Detection and Characterization of Influenza B Virus with Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz493.	0.9	1
57	Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. <i>Blood Advances</i> , 2019, 3, 1858-1867.	5.2	25
58	CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLEUCLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS. <i>Hematological Oncology</i> , 2019, 37, 308-310.	1.7	4
59	MULTI-CENTER PHASE II STUDY OF ORAL AZACITIDINE (CC-486) PLUS CHOP AS INITIAL TREATMENT FOR PERIPHERAL T-CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 560-561.	1.7	1
60	Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 466-473.	2.0	4
61	Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2019, 54, 1058-1066.	2.4	30
62	Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e60-e64.	2.0	13
63	Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial. <i>Blood</i> , 2019, 134, 5642-5642.	1.4	3
64	A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4033-4033.	1.4	2
65	Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel. <i>Blood</i> , 2019, 134, 2883-2883.	1.4	15
66	Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tisagenlecleucel on an Expanded Access Program. <i>Blood</i> , 2019, 134, 4071-4071.	1.4	6
67	Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). <i>Blood</i> , 2019, 134, 242-242.	1.4	8
68	Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. <i>Blood</i> , 2019, 134, 4103-4103.	1.4	24
69	Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution. <i>Blood</i> , 2019, 134, 5644-5644.	1.4	0
70	Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS. <i>Blood</i> , 2019, 134, 3324-3324.	1.4	0
71	Masp-2 Levels Following Allogeneic Hematopoietic Stem Cell Transplantation in Adults: Correlation with Development of a Thrombotic Microangiopathy and Implications for Therapy with Anti-Complement Agents. <i>Blood</i> , 2019, 134, 3305-3305.	1.4	0
72	Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. <i>Bone Marrow Transplantation</i> , 2018, 53, 449-456.	2.4	92

#	ARTICLE	IF	CITATIONS
73	Mycobacterial spindle cell pseudotumour: epidemiology and clinical outcomes. <i>Journal of Clinical Pathology</i> , 2018, 71, 626-630.	2.0	26
74	Validating and implementing the use of an infusion pump for the administration of thawed hematopoietic progenitor cells—a single-institution experience. <i>Transfusion</i> , 2018, 58, 339-344.	1.6	2
75	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 997-1004.	2.0	18
76	Colonization With Levofloxacin-resistant Extended-spectrum β -Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2018, 67, 1720-1728.	5.8	34
77	The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data. <i>Leukemia and Lymphoma</i> , 2018, 59, 256-258.	1.3	7
78	Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 288-293.	2.0	13
79	Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 359-365.	2.0	20
80	Earlier may be better: the role of extracorporeal photopheresis (ECP) as prevention of GVHD after allogeneic transplant. <i>Leukemia and Lymphoma</i> , 2018, 59, 272-273.	1.3	4
81	1581. Impact of Colonization with Fluoroquinolone-Resistant Enterobacteriaceae on the Risk of Gram-Negative Bacteremia in Hematopoietic Stem Cell Transplant Recipients Who Receive Prophylactic Levofloxacin. <i>Open Forum Infectious Diseases</i> , 2018, 5, S494-S494.	0.9	0
82	Hematopoietic Recovery after in-Vivo T-Cell Depleted Allogeneic Stem Cell Transplant-Effects of Major ABO Incompatibility, CMV Viremia and Acute Gvhd. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S337.	2.0	0
83	Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. <i>Leukemia and Lymphoma</i> , 2018, 59, 2829-2835.	1.3	0
84	Safety and efficacy of plerixafor dose escalation for the mobilization of CD34 ⁺ hematopoietic progenitor cells in patients with sickle cell disease: interim results. <i>Haematologica</i> , 2018, 103, 770-777.	3.5	47
85	Results from the Myeloproliferative Neoplasm Patient Care Survey: Patient Care Opportunities and Challenges. <i>Blood</i> , 2018, 132, 4289-4289.	1.4	1
86	Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?. <i>Blood</i> , 2018, 132, 2172-2172.	1.4	1
87	Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1435-1435.	1.4	1
88	Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1640-1640.	1.4	0
89	Correlations between Pre-Transplant Treatment and Bone Marrow Response with Post-Transplant Outcomes in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 4391-4391.	1.4	0
90	CCR5 delta32 Cord & Haploidentical Grafts: Allogeneic Stem Cell Transplant for HIV+ /AML Patient: A Case Report from the Impaact P1107 Observational Study. <i>Blood</i> , 2018, 132, 2184-2184.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Cord blood chimerism and relapse after haplo-cord transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 288-297.	1.3	17
92	Clofarabine as a bridge to hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2017, 58, 230-232.	1.3	3
93	A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 930-937.	2.0	10
94	Maternal microchimerism is prevalent in cord blood in memory T cells and other cell subsets, and persists post-transplant. <i>Oncolmmunology</i> , 2017, 6, e1311436.	4.6	38
95	The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. <i>Transplantation</i> , 2017, 101, e34-e38.	1.0	14
96	Against the odds: haplo-cord grafts protect from GvHD and relapse. <i>Bone Marrow Transplantation</i> , 2017, 52, 1590-1591.	2.4	4
97	Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and donors. <i>Bone Marrow Transplantation</i> , 2017, 52, 1643-1650.	2.4	63
98	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e431-e442.	4.6	132
99	Haplo-cord transplant: HLA-matching determines graft dominance. <i>Leukemia and Lymphoma</i> , 2017, 58, 1512-1514.	1.3	7
100	Second allogeneic transplantation: ever? never? or sometimes. <i>Leukemia and Lymphoma</i> , 2017, 58, 1279-1280.	1.3	1
101	Engraftment for CD34 selected stem cell products is not compromised by cryopreservation. <i>Transfusion</i> , 2016, 56, 893-898.	1.6	8
102	HLA: revisiting an old suspect in the complex pathogenesis of posttransplant lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2016, 57, 2241-2242.	1.3	0
103	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
104	Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 297-303.	0.4	19
105	DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 965-970.	2.0	52
106	Implementation of Molecular Surveillance After a Cluster of Fatal Toxoplasmosis at 2 Neighboring Transplant Centers. <i>Clinical Infectious Diseases</i> , 2016, 63, 565-568.	5.8	24
107	Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. <i>Haematologica</i> , 2016, 101, 634-643.	3.5	30
108	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76

#	ARTICLE	IF	CITATIONS
109	Haploidentical cord transplantationâ€”The best of both worlds. <i>Seminars in Hematology</i> , 2016, 53, 257-266.	3.4	24
110	Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2100-2103.	2.0	42
111	Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task. <i>Bone Marrow Transplantation</i> , 2016, 51, 1342-1349.	2.4	7
112	Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1065-1072.	2.0	20
113	Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2016, 57, 2555-2559.	1.3	12
114	Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalanâ€”Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 456-461.	2.0	18
115	Allografting versus Autografting for Follicular Lymphoma: Anâ€”Ongoing Conundrum. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2035-2036.	2.0	0
116	A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration. <i>Transfusion</i> , 2015, 55, 2010-2016.	1.6	15
117	How we handled the dextran shortage: an alternative washing or dilution solution for cord blood infusions. <i>Transfusion</i> , 2015, 55, 1147-1153.	1.6	18
118	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 552-558.	2.0	12
119	A new â€œageâ€”for high dose therapy and autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 2233-2234.	1.3	0
120	Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2015, 50, 1227-1234.	2.4	109
121	Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly maligned. <i>Leukemia and Lymphoma</i> , 2015, 56, 841-842.	1.3	5
122	Topping it up: methods to improve cord blood transplantation outcomes by increasing the number of CD34+ cells. <i>Cytotherapy</i> , 2015, 17, 723-729.	0.7	8
123	Alternative Donor Transplantationâ€”â€œMixing and Matchingâ€”the Role of Combined Cord Blood and Haplo-Identical Donor Transplantation (Haplo-Cord SCT) as a Treatment Strategy for Patients Lacking Standard Donors?. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 1-7.	2.3	10
124	Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy. <i>Journal of Clinical Virology</i> , 2015, 71, 51-58.	3.1	36
125	Predictors and GVL Effects of UCB Chimerism after Haplo-Cord Transplant. <i>Blood</i> , 2015, 126, 4385-4385.	1.4	2
126	Refractory T-Cell Prolymphocytic Leukemia with JAK3 Mutation: In Vitro and Clinical Synergy of Tofacitinib and Ruxolitinib. <i>Blood</i> , 2015, 126, 5486-5486.	1.4	10

#	ARTICLE	IF	CITATIONS
127	The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. <i>Leukemia and Lymphoma</i> , 2014, 55, 2858-2865.	1.3	30
128	Naturally acquired microchimerism. <i>Chimerism</i> , 2014, 5, 24-39.	0.7	36
129	Great expectations? Conditioning with busulfan, melphalan and thiotepa in recurrent Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 476-477.	1.3	0
130	Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2014, 55, 2866-2873.	1.3	17
131	To the end of chronic lymphocytic leukemia: what should be the role of allogeneic transplant?. <i>Leukemia and Lymphoma</i> , 2014, 55, 1221-1222.	1.3	0
132	A strategy to reduce donor-specific HLA Abs before allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 722-724.	2.4	23
133	Controversies in Multiple Myeloma: to Transplant or Not?. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 360-367.	2.3	4
134	Allotransplantation for Patients Age ≥ 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
135	Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. <i>Haematologica</i> , 2014, 99, 1373-1379.	3.5	213
136	Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50. <i>Blood</i> , 2014, 124, 1235-1235.	1.4	3
137	Haplo+cord transplantation: Neutrophil and platelet recovery and long-term survival compared to double umbilical cord blood (UCB) transplantation—A case-cohort analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7004-7004.	1.6	4
138	Haplo-cord Transplantation: Overcoming the Limitations of Umbilical Cord Blood (UCB) Transplantation (UCBT). <i>Pancreatic Islet Biology</i> , 2014, , 211-220.	0.3	0
139	Characterization of Tcra and Tcrb Repertoires in Acute Myeloid Leukemia Patients before and after Combined Haploidentical and Umbilical Cord Blood Transplant. <i>Blood</i> , 2014, 124, 2503-2503.	1.4	0
140	The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience-University of Chicago. <i>Blood</i> , 2014, 124, 2509-2509.	1.4	2
141	Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 565-73.	0.3	30
142	A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2013, 48, 1437-1443.	2.4	18
143	Pilot Study of Comprehensive Geriatric Assessment (CGA) in Allogeneic Transplant: CGA Captures a High Prevalence of Vulnerabilities in Older Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 429-434.	2.0	111
144	Autologous stem cell transplant in human immunodeficiency virus-positive patients with lymphoid malignancies: focus on infectious complications. <i>Leukemia and Lymphoma</i> , 2013, 54, 885-888.	1.3	6

#	ARTICLE	IF	CITATIONS
145	Umbilical Cord Blood Transplantation Supported by Third-Party Donor Cells: Rationale, Results, and Applications. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 682-691.	2.0	35
146	Distinct functions of erythropoietin and stem cell factor are linked to activation of mTOR kinase signaling pathway in human erythroid progenitors. <i>Cytokine</i> , 2013, 61, 329-335.	3.2	8
147	Immune reconstitution after combined haploidentical and umbilical cord blood transplant. <i>Leukemia and Lymphoma</i> , 2013, 54, 1242-1249.	1.3	23
148	Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation. <i>Case Reports in Hematology</i> , 2013, 2013, 1-3.	0.4	2
149	Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3100-3109.	1.6	206
150	Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 56-62.	2.5	39
151	Microchimerism and allogeneic transplantation. <i>Chimerism</i> , 2013, 4, 109-110.	0.7	2
152	Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. <i>Blood</i> , 2013, 122, 3863-3870.	1.4	153
153	Pilot Study Of Regulatory T Cell Depletion In The Setting Of Autologous Stem Cell Transplantation For Multiple Myeloma. <i>Blood</i> , 2013, 122, 4607-4607.	1.4	2
154	Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis. <i>Bone Marrow Transplantation</i> , 2012, 47, 1455-1458.	2.4	17
155	Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 1552-1557.	1.3	27
156	Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2012, 47, 217-226.	2.4	31
157	cGVHD of skin: simple tools, great advances. <i>Blood</i> , 2012, 120, 2537-2538.	1.4	0
158	Addition of Plerixafor to Mobilization Regimens in Autologous Peripheral Blood Stem Cell Transplants Does Not Affect the Correlation of Preharvest Hematopoietic Precursor Cell Enumeration with First-Harvest CD34+ Stem Cell Yield. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1867-1875.	2.0	12
159	Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1255-1264.	2.0	27
160	Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. <i>Leukemia and Lymphoma</i> , 2012, 53, 371-380.	1.3	27
161	Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. <i>Leukemia and Lymphoma</i> , 2012, 53, 158-159.	1.3	12
162	High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML). <i>Leukemia and Lymphoma</i> , 2012, 53, 445-450.	1.3	20

#	ARTICLE	IF	CITATIONS
163	Phase III Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 913-921.	2.0	40
164	Listen to Thy Patient: Poor Quality of Life (QoL) Reported by Older Adults Prior to Allogeneic Stem Cell Transplantation (allo-HCT) Is Independently Associated with Worse Transplant Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S227.	2.0	0
165	A Center Specific Guide Successfully Informs Patients About Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S385.	2.0	0
166	Influence of related donor age on outcomes after peripheral blood stem cell transplantation. <i>Cytotherapy</i> , 2012, 14, 707-715.	0.7	16
167	Association of clofarabine (Clo)-associated GFR decline (GFRd) with dose and AUC. <i>Journal of Clinical Oncology</i> , 2012, 30, e13120-e13120.	1.6	0
168	Immune-reconstitution after combined haploidentical and umbilical cord blood transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 6535-6535.	1.6	1
169	Identification of High Risk HLA Class I Amino Acid Substitutions in Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 3050-3050.	1.4	0
170	Allogeneic transplant for peripheral T-cell lymphoma: a sparkle of hope and many questions. <i>Leukemia and Lymphoma</i> , 2011, 52, 1415-1417.	1.3	0
171	Cord blood transplant: the glass is half full" can we do better?. <i>Leukemia and Lymphoma</i> , 2011, 52, 554-555.	1.3	4
172	Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 1025-1048.	2.2	12
173	Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. <i>Blood</i> , 2011, 118, 6438-6445.	1.4	158
174	Stem cell transplantation for indolent lymphoma. <i>Blood Reviews</i> , 2011, 25, 223-228.	5.7	2
175	Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 124-132.	2.0	26
176	Older Sibling Donors Remain an Excellent Option: Older Donor Age and Lower CD34 Infused Do Not Adversely Impact Outcomes for Matched Sibling Peripheral Blood Stem Cell (PBSC) Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S289.	2.0	0
177	HLA Antibodies in Combined Related Haploidentical-Unrelated Umbilical Cord Stem Cell Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S301.	2.0	0
178	Features of Frailty Are Surprisingly Common in Adults 50 Years and Older Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in the Modern Era. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S302.	2.0	7
179	National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 443-454.	2.0	39
180	Progressive Improvement in Cutaneous and Extracutaneous Chronic Graft-versus-Host Disease after a 24-Week Course of Extracorporeal Photopheresis"Results of a Crossover Randomized Study. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1775-1782.	2.0	127

#	ARTICLE	IF	CITATIONS
181	Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. <i>Current Opinion in Oncology</i> , 2011, 23, 681-691.	2.4	12
182	Personalized Treatment of Lymphoma: Promise and Reality. <i>Seminars in Oncology</i> , 2011, 38, 225-235.	2.2	10
183	Alemtuzumab in allogeneic hematopoietic stem cell transplantation. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1099-1111.	3.1	31
184	T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. <i>Leukemia and Lymphoma</i> , 2011, 52, 214-222.	1.3	16
185	T-Cellâ€œDepleted Reduced-Intensity Conditioning Transplantation for Lymphoma: Do Donor Lymphocyte Infusions Really Matter?. <i>Journal of Clinical Oncology</i> , 2011, 29, e243-e243.	1.6	1
186	A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. <i>Blood</i> , 2011, 118, 496-496.	1.4	0
187	Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 1038-1046.	1.6	290
188	Temsirolimus Has Activity in Nonâ€œMantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium. <i>Journal of Clinical Oncology</i> , 2010, 28, 4740-4746.	1.6	181
189	Stem-Cell Transplantation for Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2010, 362, 955-956.	27.0	15
190	The Next Frontier for Stem Cell Transplantation. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1421.	7.4	14
191	Donor Policies for Stem Cell Transplantationâ€œReply. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 524.	7.4	0
192	Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. <i>Leukemia and Lymphoma</i> , 2010, 51, 2240-2249.	1.3	40
193	Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2010, 45, 1068-1076.	2.4	38
194	Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. <i>Bone Marrow Transplantation</i> , 2010, 45, 1692-1698.	2.4	24
195	A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B-Cell Lymphoma: A Report from the CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 35-45.	2.0	88
196	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 443-468.	2.0	60
197	Introduction to the Reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 563-564.	2.0	22
198	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1467-1503.	2.0	125

#	ARTICLE	IF	CITATIONS
199	Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. <i>Leukemia and Lymphoma</i> , 2010, 51, 1241-1250.	1.3	16
200	Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2010, 51, 995-1006.	1.3	16
201	Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104. <i>Blood</i> , 2010, 116, 37-37.	1.4	31
202	Autologous (auto) Versus Allogeneic (allo) Hematopoietic Cell Transplantation (HCT) for T-NHL: A CIBMTR Analysis. <i>Blood</i> , 2010, 116, 689-689.	1.4	3
203	Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. <i>Leukemia and Lymphoma</i> , 2009, 50, 1809-1817.	1.3	50
204	Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 610-618.	2.5	18
205	Fatal CMV pneumonitis in a lymphoma patient treated with rituximab. <i>American Journal of Hematology</i> , 2009, 84, 614-616.	4.1	13
206	Autologous transplant for primary mediastinal B-cell lymphoma. <i>Expert Review of Hematology</i> , 2009, 2, 31-36.	2.2	4
207	Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 109-117.	2.0	98
208	BK Virus Infection is Associated with Hematuria and Renal Impairment in Recipients of Allogeneic Hematopoietic Stem Cell Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 9.	2.0	0
209	Geriatric Assessment (GA) May Identify Vulnerable Older Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 102-103.	2.0	3
210	Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Unexpected Renal Toxicity. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 105.	2.0	3
211	Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 554-563.	2.0	33
212	Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 610-617.	2.0	58
213	Methodological and Logistical Considerations to Study Design and Data Collection in Racial/Ethnic Minority Populations Evaluating Outcome Disparity in Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 903-909.	2.0	4
214	BK Virus Infection Is Associated with Hematuria and Renal Impairment in Recipients of Allogeneic Hematopoietic Stem Cell Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1038-1048.e1.	2.0	80
215	Older Age But Not Donor Health Impairs Allogeneic Granulocyte Colony-Stimulating Factor (G-CSF) Peripheral Blood Stem Cell Mobilization. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1394-1399.	2.0	55
216	Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1455-1464.	2.0	52

#	ARTICLE	IF	CITATIONS
217	Advances in mobilization for the optimization of autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2009, 50, 1412-1421.	1.3	48
218	Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 85-91.	1.3	12
219	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 5074-5082.	1.4	143
220	Reduced-Intensity and Nonmyeloablative Conditioning Regimens. <i>Cancer Treatment and Research</i> , 2009, 144, 209-232.	0.5	3
221	A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study.. <i>Blood</i> , 2009, 114, 2238-2238.	1.4	1
222	Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. <i>Bone Marrow Transplantation</i> , 2008, 41, 505-513.	2.4	48
223	Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 236-245.	2.0	157
224	159: Feasibility of Clofarabine Cyto-reduction before Initiation of Allogeneic Stem Cell Transplant Regimen During the Cytopenic Phase for Patients with Refractory Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 60.	2.0	0
225	Granulocyte Colony-Stimulating Factor-Based Stem Cell Mobilization in Patients with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 719-723.	2.0	20
226	Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 904-912.	2.0	56
227	Paucity of HLA-Identical Unrelated Donors for African-Americans with Hematologic Malignancies: The Need for New Donor Options. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 938-941.	2.0	55
228	Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1209-1216.	2.0	75
229	Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1323-1333.	2.0	44
230	Epidemiology of Vancomycin-Resistant Enterococci Among Patients on an Adult Stem Cell Transplant Unit: Observations From an Active Surveillance Program. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, 1019-1025.	1.8	24
231	Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. <i>Leukemia and Lymphoma</i> , 2008, 49, 52-58.	1.3	37
232	Osteopontin Regulates Actin Cytoskeleton and Contributes to Cell Proliferation in Primary Erythroblasts. <i>Journal of Biological Chemistry</i> , 2008, 283, 6997-7006.	3.4	38
233	Superiority of Reduced-Intensity Conditioning for Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 4045-4046.	1.6	0
234	Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. <i>Leukemia and Lymphoma</i> , 2008, 49, 531-537.	1.3	11

#	ARTICLE	IF	CITATIONS
235	2007: The year in review for<i>Leukemia and Lymphoma</i>. Leukemia and Lymphoma, 2008, 49, 1-3.	1.3	2
236	Late relapse following allogeneic transplant for chronic lymphocytic leukemia: How good are graft versus leukemia effects?. Leukemia and Lymphoma, 2008, 49, 1651-1652.	1.3	0
237	A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood, 2008, 112, 2667-2674.	1.4	320
238	Nonmyeloablative conditioning for relapsed follicular lymphoma. Blood, 2008, 112, 2585-2586.	1.4	3
239	Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis. Blood, 2008, 112, 2809-2809.	1.4	18
240	Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors. Blood, 2008, 112, 3015-3015.	1.4	1
241	Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHCT) for Patients Relapsing after Autologous Stem Cell Transplantation (autoHCT) for B Cell Non-Hodgkin Lymphoma (NHL). Blood, 2008, 112, 459-459.	1.4	1
242	Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (Hct) in Patients with Advanced Hematologic Malignancies: A Phase I&II Study. Blood, 2008, 112, 4381-4381.	1.4	1
243	Identifying Amino Acid Substitution Positions Associated with Day 100 Survival in Unrelated Donor Stem Cell Transplant Using Random Forest Analysis. Blood, 2008, 112, 3012-3012.	1.4	0
244	mTOR Inhibition in Lymphoma: A Rational and Promising Strategy. Letters in Drug Design and Discovery, 2007, 4, 224-231.	0.7	3
245	Interdigitating dendritic cell tumors in two patients exposed to topical calcineurin inhibitors. Leukemia and Lymphoma, 2007, 48, 816-818.	1.3	13
246	Follicular lymphoma: a historical overview. Leukemia and Lymphoma, 2007, 48, 232-243.	1.3	9
247	Cardiac tamponade in a patient with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2007, 48, 829-832.	1.3	3
248	28: A multicenter prospective randomized Phase II study in patients with corticosteroid-refractory/dependent/intolerant chronic cutaneous GVHD given either extracorporeal photoimmune therapy with UVADEX® in conjunction with conventional therapy or conventional therapy alone. Biology of Blood and Marrow Transplantation, 2007, 13, 13.	2.0	0
249	223: C-reactive protein (CRP) may predict transplant-related mortality after allogeneic hematopoietic cell transplant (HCT). Biology of Blood and Marrow Transplantation, 2007, 13, 82.	2.0	0
250	Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leukemia and Lymphoma, 2007, 48, 1799-1805.	1.3	16
251	Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Annals of Oncology, 2007, 18, 1071-1079.	1.2	232
252	Chimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplantation, 2007, 40, 181-181.	2.4	7

#	ARTICLE	IF	CITATIONS
253	Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 40, 1027-1032.	2.4	74
254	Alemtuzumab Reduces Chronic Graft Versus Host Disease (cGVHD) and Treatment Related Mortality (TRM) after Reduced Intensity Conditioning for AML and MDS.. <i>Blood</i> , 2007, 110, 1076-1076.	1.4	2
255	Prospective Measurement of BK Virus Blood and Urine Levels, and Associations with Morbidity, in Recipients of Allogeneic Hematopoietic Stem Cell Transplants.. <i>Blood</i> , 2007, 110, 1973-1973.	1.4	0
256	Unrelated Donor (URD) Searches in African-Americans with Hematologic Malignancies: Paucity of HLA Identical Donors.. <i>Blood</i> , 2007, 110, 5064-5064.	1.4	0
257	Standardizing chronic graft-versus-host disease. <i>Future Oncology</i> , 2006, 2, 459-462.	2.4	3
258	Toxicity of high dose BCNU: How much is too much?. <i>Leukemia and Lymphoma</i> , 2006, 47, 1447-1448.	1.3	3
259	Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. <i>Lancet Oncology</i> , The, 2006, 7, 436-438.	10.7	37
260	The relationship of day 30 and day 100 donor chimerism to clinical outcomes following reduced-intensity allogeneic transplantation for hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 34.	2.0	0
261	Prior invasive fungal infection does not preclude successful allogeneic transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 34.	2.0	110
262	Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 541-551.	2.0	84
263	Performance Status and Comorbidity Predict Transplant-Related Mortality After Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 954-964.	2.0	122
264	Autologous transplantation for follicular lymphoma? Not too soon!. <i>Blood</i> , 2006, 108, 2496-2497.	1.4	1
265	Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2006, 132, 747-754.	2.5	8
266	Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. <i>Bone Marrow Transplantation</i> , 2006, 37, 307-310.	2.4	42
267	Severe intestinal graft-versus-host disease following autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006, 38, 391-392.	2.4	6
268	The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. <i>Blood Reviews</i> , 2006, 20, 235-244.	5.7	22
269	Fatigue and Physical Activity in Patients Undergoing Hematopoietic Stem Cell Transplant. <i>Oncology Nursing Forum</i> , 2006, 33, 614-624.	1.2	122
270	Molecular Inhibition of mTOR with Temsirolimus (TORISELâ„¢, CCI-779) Is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium.. <i>Blood</i> , 2006, 108, 2483-2483.	1.4	3

#	ARTICLE	IF	CITATIONS
271	Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia.. Blood, 2006, 108, 4923-4923.	1.4	3
272	New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2006, 108, 3675-3675.	1.4	0
273	Pre-Transplant Biomarkers Predict GVHD and Treatment-Related Mortality in Patients Treated with Extracorporeal Photopheresis Prior to Allogeneic Bone Marrow Transplantation.. Blood, 2006, 108, 5182-5182.	1.4	0
274	Superior Survival after Autologous vs. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Diffuse Large B-Cell Lymphoma (DLBCL) Not Explained by Differences in Chemosensitivity.. Blood, 2006, 108, 3021-3021.	1.4	6
275	Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplantation, 2005, 35, 253-260.	2.4	41
276	Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplantation, 2005, 35, 965-970.	2.4	53
277	Unrelated donor transplantation over the age of 55. Are we merely getting (b)older?. Leukemia, 2005, 19, 31-33.	7.2	18
278	Hematopoietic Stem Cell Transplantation for Myelofibrosis. Seminars in Oncology, 2005, 32, 414-421.	2.2	15
279	Therapeutic options for patients with hodgkinâ€™s disease and non-hodgkinâ€™s lymphoma who relapse after autologous transplant. Current Treatment Options in Oncology, 2005, 6, 279-287.	3.0	1
280	Simultaneous Generation of CD8+ and CD4+ Melanoma-Reactive T Cells by Retroviral-Mediated Transfer of a Single T-Cell Receptor. Cancer Research, 2005, 65, 1570-1576.	0.9	97
281	Fludarabine, Melphalan, and Alemtuzumab Conditioning in Adults With Standard-Risk Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome. Journal of Clinical Oncology, 2005, 23, 5728-5738.	1.6	134
282	Arterial thrombosis in four patients treated with thalidomide. Leukemia and Lymphoma, 2005, 46, 239-242.	1.3	47
283	A multi-institutional study of extracorporeal photoimmune therapy (ECP) with UVADEXÂ® for the prevention of acute GVHD in patients (pts) undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation (AHCT). Biology of Blood and Marrow Transplantation, 2005, 11, 37.	2.0	0
284	Ganciclovir and high-dose valacyclovir reduce cytomegalovirus reactivation in patients receiving allogeneic stem cell transplantation with Campath-1Hâ€™-based conditioning regimens. Biology of Blood and Marrow Transplantation, 2005, 11, 94.	2.0	2
285	Differences in Characteristics of US Hematopoietic Stem Cell Transplantation Centers by Proportion of Racial or Ethnic Minorities. Biology of Blood and Marrow Transplantation, 2005, 11, 988-998.	2.0	11
286	Autologous and allogeneic stem cell transplantation in follicular lymphoma. Transfusion and Apheresis Science, 2005, 32, 45-53.	1.0	3
287	Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.. Blood, 2005, 106, 2022-2022.	1.4	1
288	Reduced Intensity vs Myeloablative Conditioning for HLA Matched Sibling Transplantation in Follicular Lymphoma.. Blood, 2005, 106, 656-656.	1.4	11

#	ARTICLE	IF	CITATIONS
289	Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation.. Blood, 2005, 106, 1818-1818.	1.4	0
290	Autocrine Signaling by Osteopontin Regulates Actin Remodeling in Human Primary Erythroid Progenitors.. Blood, 2005, 106, 1667-1667.	1.4	0
291	Low-Grade Lymphoma. Hematology American Society of Hematology Education Program, 2004, 2004, 203-220.	2.5	47
292	Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplantation, 2004, 33, 1015-1023.	2.4	47
293	Stem cell transplantation in follicular lymphoma: progress at last?. Bone Marrow Transplantation, 2004, 34, 929-938.	2.4	20
294	Long-term follow up after non-myeloablative allogeneic stem cell transplantation for renal cell carcinoma: the university of Chicago experience. Biology of Blood and Marrow Transplantation, 2004, 10, 10.	2.0	0
295	A multi-institutional study of extracorporeal photophoresis (ECP) with Uvadex® for the prevention of acute graft vs. host disease (aGvHD) in patients (pts) undergoing allogeneic hematopoietic progenitor cell transplants (allo-HPCT) with myeloablative conditioning. Biology of Blood and Marrow Transplantation, 2004, 10, 53.	2.0	0
296	Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 2004, 10, 386-394.	2.0	12
297	Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood, 2004, 103, 4373-4374.	1.4	6
298	Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood, 2004, 104, 3797-3803.	1.4	108
299	Autologous transplantation for newly diagnosed follicular lymphoma: cure at last or not yet?. Blood, 2004, 104, 2613-2614.	1.4	0
300	Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).. Blood, 2004, 104, 1145-1145.	1.4	11
301	Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.. Blood, 2004, 104, 2321-2321.	1.4	1
302	Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas.. Blood, 2004, 104, 918-918.	1.4	2
303	Distinct Functions of Erythropoietin and Stem Cell Factor Are Linked to Activation of p70S6/mTOR Kinase Signaling Pathway in Primary Erythroid Progenitors.. Blood, 2004, 104, 2175-2175.	1.4	0
304	Conditioning with Fludarabine (Flu)-Alkylator Is More Effective Cytoreduction Than Cyclophosphamide-Total Body Irradiation (Cy/TBI) for Refractory, Progressive Chronic Lymphatic Leukemia (CLL).. Blood, 2004, 104, 5045-5045.	1.4	0
305	The University of Chicago experience with a reduced intensity allogeneic peripheral blood stem cell transplant preparative regimen using fludarabine, cyclophosphamide, and antithymocyte globulin (ATG) in pts with a hematologic malignancy. Journal of Clinical Oncology, 2004, 22, 6626-6626.	1.6	0
306	Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer, 2003, 97, 1242-1247.	4.1	49

#	ARTICLE	IF	CITATIONS
307	Thrombotic thrombocytopenic purpura after cephalosporin administration: a possible relationship. <i>Transfusion</i> , 2003, 43, 1317-1321.	1.6	7
308	Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. <i>Bone Marrow Transplantation</i> , 2003, 31, 813-816.	2.4	14
309	Safety and outcome after fludarabineâ€“thiotepaâ€“TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. <i>Bone Marrow Transplantation</i> , 2003, 32, 9-13.	2.4	9
310	Regimen-related toxicity after fludarabineâ€“melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. <i>Bone Marrow Transplantation</i> , 2003, 32, 471-476.	2.4	45
311	Clinical activity of arsenic trioxide in Burkitt-like lymphoma. <i>Leukemia</i> , 2003, 17, 271-272.	7.2	16
312	Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. <i>Blood</i> , 2003, 102, 3521-3529.	1.4	339
313	Syngeneic Hematopoietic Stem-Cell Transplantation for Non-Hodgkinâ€™s Lymphoma: A Comparison With Allogeneic and Autologous Transplantationâ€”The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2003, 21, 3744-3753.	1.6	146
314	A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. <i>Blood</i> , 2003, 101, 2476-2482.	1.4	155
315	Transplantation for myelofibrosis: yes! But for whom?. <i>Blood</i> , 2003, 102, 3857-3857.	1.4	0
316	Non-Hodgkinâ€™s Lymphoma. , 2003, , 295-318.		0
317	Cutting Edge: Activation of the p38 Mitogen-Activated Protein Kinase Signaling Pathway Mediates Cytokine-Induced Hemopoietic Suppression in Aplastic Anemia. <i>Journal of Immunology</i> , 2002, 168, 5984-5988.	0.8	93
318	Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2002, 99, 2255-2258.	1.4	148
319	Reduced duration of cytopenias following melphalan conditioning and autografting for multiple myeloma. <i>Blood</i> , 2002, 99, 4251-4252.	1.4	0
320	Autologous and allogeneic transplantation for aggressive NHL. <i>Cytotherapy</i> , 2002, 4, 223-240.	0.7	13
321	Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. <i>Biochemical and Biophysical Research Communications</i> , 2002, 297, 760-764.	2.1	40
322	Pilot Trial of Interleukin-2 With Granulocyte Colony-Stimulating Factor for the Mobilization of Progenitor Cells in Advanced Breast Cancer Patients Undergoing High-Dose Chemotherapy: Expansion of Immune Effectors Within the Stem-Cell Graft and Postâ€“Stem-Cell Infusion. <i>Journal of Clinical Oncology</i> , 2001, 19, 634-644.	1.6	34
323	Primary Mediastinal B-Cell Lymphoma: A Review of Pathology and Management. <i>Journal of Clinical Oncology</i> , 2001, 19, 1855-1864.	1.6	129
324	Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. <i>Blood</i> , 2001, 98, 1695-1700.	1.4	202

#	ARTICLE	IF	CITATIONS
325	Autologous Transplantation for Diffuse Aggressive Non-Hodgkin's Lymphoma in Patients Never Achieving Remission: A Report from the Autologous Blood and Marrow Transplant Registry. <i>Journal of Clinical Oncology</i> , 2001, 19, 406-413.	1.6	194
326	Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2001, 67, 227-233.	4.1	23
327	Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. <i>Bone Marrow Transplantation</i> , 2001, 27, 397-404.	2.4	14
328	Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). <i>Bone Marrow Transplantation</i> , 2001, 27, 387-396.	2.4	106
329	Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2001, 28, 557-562.	2.4	34
330	Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions. <i>Bone Marrow Transplantation</i> , 2001, 28, 545-549.	2.4	62
331	Allogeneic and autologous transplantation for chronic lymphocytic leukemia. <i>Leukemia</i> , 2001, 15, 1317-1325.	7.2	36
332	STEM CELL TRANSPLANTATION ELIMINATES ALLOANTIBODY IN A HIGHLY SENSITIZED PATIENT ¹ . <i>Transplantation</i> , 2001, 72, 1653-1655.	1.0	13
333	Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. <i>Bone Marrow Transplantation</i> , 2000, 26, 445-449.	2.4	91
334	High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. <i>Bone Marrow Transplantation</i> , 2000, 26, 333-338.	2.4	8
335	Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: Potential for nonablative preparative regimens. <i>Current Oncology Reports</i> , 2000, 2, 182-191.	4.0	6
336	Allogeneic Transplantation for Low-Grade Lymphoma: Long-Term Follow-Up. <i>Journal of Clinical Oncology</i> , 2000, 18, 702-702.	1.6	19
337	Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 190-197.	2.0	19
338	Autotransplants for Hodgkin's Disease in Patients Never Achieving Remission: A Report From the Autologous Blood and Marrow Transplant Registry. <i>Journal of Clinical Oncology</i> , 1999, 17, 534-534.	1.6	186
339	Risk Factors for Acute Graft-Versus-Host Disease After Allogeneic Blood Stem Cell Transplantation. <i>Blood</i> , 1999, 94, 1465-1470.	1.4	217
340	Intensive Dose Ifosfamide and Etoposide with G-CSF for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1999, 35, 317-324.	1.3	15
341	Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. <i>Annals of Oncology</i> , 1999, 10, 527-529.	1.2	48
342	Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 1999, 23, 977-981.	2.4	22

#	ARTICLE	IF	CITATIONS
343	Toxicity of single daily dose gentamicin in stem cell transplantation. Bone Marrow Transplantation, 1999, 24, 57-61.	2.4	9
344	Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplantation, 1999, 24, 763-768.	2.4	66
345	STEM CELL TRANSPLANTATION FOR A HIGHLY SENSITIZED PATIENT. Transplantation, 1999, 67, S14.	1.0	1
346	Risk Factors for Acute Graft-Versus-Host Disease After Allogeneic Blood Stem Cell Transplantation. Blood, 1999, 94, 1465-1470.	1.4	11
347	Conventional and High Dose Chemotherapy for Lymphomas. , 1999, , 300-312.		0
348	High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.. Journal of Clinical Oncology, 1998, 16, 63-69.	1.6	58
349	Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.. Journal of Clinical Oncology, 1998, 16, 986-993.	1.6	237
350	Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma. Blood, 1998, 91, 1178-1184.	1.4	265
351	Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood, 1998, 91, 1178-84.	1.4	70
352	Allogeneic bone marrow transplantation for low-grade lymphoma. Blood, 1998, 92, 1832-6.	1.4	190
353	Analysis of Chimerism Following Allogeneic Bone Marrow Transplantation by Fluorescent-in-Situ Hybridization. Leukemia and Lymphoma, 1997, 25, 463-467.	1.3	11
354	Invasive Aspergillus sinusitis During Bone Marrow Transplantation. Scandinavian Journal of Infectious Diseases, 1997, 29, 436-438.	1.5	24
355	Complete Remission of Refractory Gestational Trophoblastic Disease with Brain Metastases Treated with Multicycle Ifosfamide, Carboplatin, and Etoposide (ICE) and Stem Cell Rescue. Gynecologic Oncology, 1997, 65, 366-369.	1.4	34
356	Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue.. Journal of Clinical Oncology, 1997, 15, 667-673.	1.6	52
357	Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy. Blood, 1997, 89, 4531-4536.	1.4	1,101
358	Central nervous system relapse of lymphoid malignancies in adults: The role of high-dose chemotherapy. Annals of Oncology, 1997, 8, 515-524.	1.2	19
359	Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplantation, 1997, 19, 121-127.	2.4	59
360	Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplantation, 1997, 19, 455-460.	2.4	76

#	ARTICLE	IF	CITATIONS
361	Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. <i>Bone Marrow Transplantation</i> , 1997, 19, 977-982.	2.4	209
362	Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. <i>Bone Marrow Transplantation</i> , 1997, 20, 491-495.	2.4	20
363	Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. <i>British Journal of Haematology</i> , 1997, 97, 466-473.	2.5	102
364	Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. <i>Blood</i> , 1997, 89, 4531-6.	1.4	294
365	Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. <i>Biology of Blood and Marrow Transplantation</i> , 1997, 3, 150-6.	2.0	24
366	Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. <i>Cancer Journal From Scientific American</i> , 1997, 3 Suppl 1, S54-8.	0.8	0
367	Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity, and survival depend on disease histology. <i>American Journal of Medicine</i> , 1996, 100, 299-307.	1.5	106
368	Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 1996, 14, 3036-3042.	1.6	42
369	ALLOGENEIC TRANSPLANTATION FOR ADVANCED LEUKEMIA. <i>Transplantation</i> , 1996, 62, 1806-1810.	1.0	39
370	Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts [see comments]. <i>Blood</i> , 1995, 85, 1659-1665.	1.4	549
371	CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. <i>Blood</i> , 1995, 86, 4337-4343.	1.4	323
372	Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy- 1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. <i>Blood</i> , 1995, 86, 2842-2848.	1.4	272
373	A Phase 1-11 Study of High-Dose Thiotepa, Busulfan and Cyclophosphamide as a Preparative Regimen for Autologous Transplantation for Malignant Lymphoma. <i>Leukemia and Lymphoma</i> , 1995, 17, 427-433.	1.3	25
374	Intravesicular carboprost for the treatment of hemorrhagic cystitis after marrow transplantation. <i>Urology</i> , 1995, 46, 811-815.	1.0	42
375	Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy- 1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. <i>Blood</i> , 1995, 86, 2842-2848.	1.4	14
376	CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. <i>Blood</i> , 1995, 86, 4337-43.	1.4	59
377	High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. <i>Bone Marrow Transplantation</i> , 1995, 15, 549-55.	2.4	45
378	High-dose melphalan allows durable engraftment of allogeneic bone marrow. <i>Bone Marrow Transplantation</i> , 1995, 15, 321-3.	2.4	11

#	ARTICLE	IF	CITATIONS
379	Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.. Journal of Clinical Oncology, 1994, 12, 1923-1930.	1.6	45
380	Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplantation, 1994, 13, 461-4.	2.4	28
381	Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood, 1993, 82, 2324-2328.	1.4	100
382	Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood, 1993, 82, 2324-2328.	1.4	78
383	Relapsing polychondritis: A paraneoplastic syndrome associated with myelodysplastic syndromes. American Journal of Hematology, 1992, 40, 47-50.	4.1	40
384	Pregnancy associated with lupus anticoagulant and heparin induced thrombocytopenia: management with a low molecular weight heparinoid. Thrombosis Research, 1991, 62, 23-29.	1.7	24
385	Simultaneous use of Rhodamine 123, phycoerythrin, Texas red, and allophycocyanin for the isolation of human hematopoietic progenitor cells. Cytometry, 1991, 12, 179-183.	1.8	43
386	Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. Blood, 1990, 76, 1997-2004.	1.4	151
387	Preleukemic state preceding adult acute lymphoblastic leukemia. American Journal of Medicine, 1990, 89, 657-662.	1.5	3
388	Cytokine-dependent long-term culture of highly enriched precursors of hematopoietic progenitor cells from human bone marrow.. Journal of Clinical Investigation, 1990, 86, 932-941.	8.2	147
389	Characteristics of engraftment after repeated autologous bone marrow transplantation. Experimental Hematology, 1990, 18, 785-8.	0.4	4
390	Acquired Cyclic Amegakaryocytic Thrombocytopenia Associated with an Immunoglobulin Blocking the Action of Granulocyteâ€“Macrophage Colony-Stimulating Factor. New England Journal of Medicine, 1989, 321, 97-102.	27.0	47
391	Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.. Journal of Clinical Oncology, 1989, 7, 932-939.	1.6	346
392	Endoscopic Sclerotherapy of Esophageal Varices. Journal of Clinical Gastroenterology, 1988, 10, 368-372.	2.2	15